| Catalog No. |
TD-HF941036 |
| Species reactivity |
Human |
| Applications |
Research Grade Biosimilar |
| Isotype |
Fusion - [TNFRSF13B (tumor necrosis factor receptor (TNFR) superfamily member 13B, TACI, transmembrane activator and CAML Interactor)]2 - IGHG1 Fc (Fragment constant) |
| Expression system |
Mammalian Cells |
| Target |
TNF- and APOL-related leukocyte expressed ligand 2, APRIL, CD256, Tumor necrosis factor ligand superfamily member 13, TNF-related death ligand 1, TALL-2, TNFSF13, ZTNF2, A proliferation-inducing ligand, TALL2, TRDL-1, BAFF, ZTNF4, BLYS, Tumor necrosis factor ligand superfamily member 13B, Dendritic cell-derived TNF-like molecule, TALL-1, TNF- and APOL-related leukocyte expressed ligand 1, BLyS, B lymphocyte stimulator, TNFSF13B, CD257, TNFSF20, TALL1, B-cell-activating factor |
| Endotoxin level |
Please contact the lab for this information. |
| Purity |
>95% purity as determined by SDS-PAGE. |
| Purification |
Protein A/G, purified from cell culture supernatant. |
| Accession |
O75888 & Q9Y275 |
| Form |
Liquid |
| Storage buffer |
0.01M PBS,pH7.4. |
| Stability and Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
| Alternate Names |
TACI-Fc,TACI-Ig,CAS:845264-92-8 |
| Background |
Atacicept (TACI-Ig) is a is a recombinant fusion protein containing the extracellular, ligand-binding portion of the TACI receptor and the Fc portion of human IgG. Atacicept inhibits B cell stimulation by binding to B lymphocyte stimulator and a proliferation-inducing ligand. Atacicept can be used in research of B-cell autoimmune disease. |
| Note |
For research use only. Not for use in clinical or therapeutic applications. |